Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667952 · ClinicalTrials.gov registry record
Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness
A clinical trial of Pediatric or Young Adult Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 1,068
- Enrollment target
- 1
- Study location
NCT01667952: Completed study of Pediatric or Young Adult Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01667952 is a study of Pediatric or Young Adult Cancer Survivors that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,068 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01667952, a study of Pediatric or Young Adult Cancer Survivors, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 1,068 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish a registry of survivors of cancer, tumor, or a related illness.
Primary Outcome
For the purpose of facilitating future genetic laboratory investigations of late effects among of survivors of cancer, tumors, or a related illness. Patients in the ALTFU Program are followed for secondary malignant neoplasms and other adverse outcomes (so-called "late effects") including cardiomyopathy, pulmonary fibrosis, cardiac valvular pathology, osteoporosis, and others. The following data will be ascertained from each study participant: (1) family history information will be ascertained u
Conditions Studied
Interventions
- OTHER Blood sample
- GENETIC Family History Questionnaire (FHQ)
- GENETIC Salvia sample
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,068 participants |
| Start Date | 2012-08 |
| Est. Completion | 2025-03-06 |
What the finished NCT01667952 record still lists
NCT01667952 is an observational study that tracks outcomes without assigning an intervention. Its 1,068 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Pediatric or Young Adult Cancer Survivors appearing as the primary indexed condition, and to 3 interventions - of which Blood sample is the first listed.
NCT01667952 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01667952 about?
NCT01667952 is a clinical study titled "Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness". The purpose of this study is to establish a registry of survivors of cancer, tumor, or a related illness.
What is the current status of trial NCT01667952?
This trial is currently completed. The enrollment target is 1,068 participants. The study started on 2012-08. Estimated completion is 2025-03-06.
What conditions does trial NCT01667952 study?
This clinical trial studies the following conditions: Pediatric or Young Adult Cancer Survivors.
What interventions are being tested in trial NCT01667952?
The interventions under investigation include: Blood sample (OTHER), Family History Questionnaire (FHQ) (GENETIC), Salvia sample (GENETIC).
Who is sponsoring clinical trial NCT01667952?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01667952 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia